2023
Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-Vitamin K Antagonist Oral AnticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized Controlled TrialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
Sipra Q, Bin Riaz I, Naqvi S, He H, Liu H, Bryce A, Murad M, McBane R. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis. Journal Of Clinical Oncology 2022, 40: e24070-e24070. DOI: 10.1200/jco.2022.40.16_suppl.e24070.Peer-Reviewed Original ResearchNet clinical benefitMixed treatment comparisonMajor bleedingClinical benefitSystematic reviewCANVAS trialOdds ratioGreater net clinical benefitRelevant non-major bleedingSignificant differencesTreatment comparisonsEffect estimatesEfficacy of DOACsNon-major bleedingVTE risk reductionVenous thromboembolism recurrenceCumulative ranking curvePatient-important outcomesConfidence intervalsMantel-Haenszel methodTreatment of catsFixed-effects modelThromboembolism recurrenceVTE recurrenceCause mortalityImpact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
Welsh R, Dehghani P, Lopes R, Wojdyla D, Aronson R, Granger C, Windecker S, Vora A, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander J, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart 2022, 9: e001892. PMID: 35172988, PMCID: PMC8852719, DOI: 10.1136/openhrt-2021-001892.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinAtrial FibrillationFactor Xa InhibitorsFemaleHemorrhageHumansIschemiaMaleMedication Therapy ManagementMiddle AgedOutcome and Process Assessment, Health CarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPreoperative PeriodPyrazolesPyridonesVitamin KConceptsOral anticoagulant useVitamin K antagonistsClinically relevant non-major bleedingAcute coronary syndromePercutaneous coronary interventionNon-major bleedingOral anticoagulantsAtrial fibrillationAUGUSTUS trialOral anticoagulation statusElective percutaneous coronary interventionHAS-BLED scoreRisk of myocardial infarctionSecondary analysisHAS-BLEDK antagonistsOpen-labelHigher CHAPrimary endpointAntithrombotic therapyAnticoagulant useClinical outcomesCoronary syndromeIschaemic eventsRandomised treatment
2020
NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Dahal K, Mosleh W, Almnajam M, Khaddr M, Adeel M, Vashist A, Robinson P, Azrin M, Lee J. NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2020, 21: 1202-1208. PMID: 32173329, DOI: 10.1016/j.carrev.2020.03.012.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionRandomized clinical trialsDual therapyTriple therapyStent thrombosisAtrial fibrillationCoronary syndromeCoronary interventionSystematic reviewRelevant non-major bleedingRisk of STComposite of mortalityConcomitant atrial fibrillationEfficacy of NOACsMajor efficacy outcomeNon-major bleedingTIMI minor bleedingDual antiplatelet therapyPrimary safety outcomeBleeding outcomesCRNM bleedingIschemic outcomesISTH majorP2Y12 agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply